The company carries out comprehensive safety inspection at the end of the year
Release time:
2020-08-14
Company Launches Year-end Comprehensive Safety Inspection
News In order to find out the safety management status of each unit more comprehensively and grasp the safety production management at the end of the year, 12# August 24 and 25 , the Group Safety Management Office organized the safety supervisors of each unit to participate, A year-end comprehensive security inspection was conducted on seven units in Jinhua.
In the inspection process of each unit of gold, in order to improve the inspection efficiency, the inspectors are divided into two groups: safety management defects and on-site safety hazard management, and each unit is inspected separately. From the overall situation, in terms of on-site hidden danger management, all units have made obvious progress this year. The production workshops, warehouses, and peripheral sites are in good order, basically eliminating major safety hazards, and the overall appearance of the factory area is more beautiful than before. However, some units also have problems such as stagnant water on the floor of the workshop, poor fire access, untimely cleaning of the site, and waste storage. In terms of safety management defects, the inspection team focused on checking the safety management ledger. The main problems included that individual units did not carry out the safety education year activities as planned. There are many missing items in management and the ledger management is chaotic. Most units have not effectively carried out safety rewards and punishments. Individual units did not carry out safety training for employees attentively. There are three units with multiple sets of safety systems, which have not been cleaned up in time to control; except for health science and technology companies, the safety investment accounts of other units are not standardized. The department's safety activity record form is not standardized.
In the past year, the safety management of international trading companies has made obvious progress, and the rectification of hidden dangers is more timely than before. In particular, the safety ledger is more standardized and detailed, which basically meets the requirements of the company's ledger management system and has been unanimously affirmed by the members of the inspection team.
During the inspection, the safety supervisors of each unit exchanged and learned from each other. After the inspection, the inspection team put forward rectification opinions and requirements to each unit. The person in charge of the safety management office of
group said that the process management in production and operation activities needs to be constantly grasped, otherwise the safety result can only be a castle in the air. Judging from the situation of this inspection, there are still many weaknesses in safety management. In order to implement standardized and strict management and overcome the phenomenon of few habitual methods and inaction in safety management, it is also necessary for safety management personnel of all units to further realize that there is a gap in their own management level and enhance their enthusiasm and willingness to pursue progress in safety management.
According to the requirements of the group company, Tianjin, Hubei, Yunnan, Anhui and other foreign enterprises have also organized self-inspection of safety and environmental protection work in the near future. (Group Security Management Office)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page